Laquinimod

  • The pivotal CONCERTO clinical study is continuing according to plan and results are expected in 2016
  • Teva is holding a number of presentations of laquinimod at the AAN Annual Meeting on April 18-25 

Tasquinimod     

  • Results from the Phase III study 10TASQ10 showed that treatment with tasquinimod reduced the risk of radiographic cancer progression or death compared to placebo (rPFS, HR=0.69, CI 95%: 0.60 - 0.80) in patients with metastatic castration resistant prostate cancer (mCRPC) who have not received chemotherapy, but did not extend overall survival (OS, HR=1.09, CI 95%: 0.94 - 1.28)
  • Further development of tasquinimod for the treatment of prostate cancer has been discontinued. The collaboration agreement with Ipsen will accordingly cease.

ISI          

  • The project is currently focusing on building up a patent portfolio

Financial summary

MSEK   Jan. - Mar.   Jan. - Dec.
  2015 2014   2014  
Net sales 2.9 2.1   10.4  
           
Operating loss -57.4 -59.2   -228.5  
Loss for the period -58.0 -60.2   -231.5  
Loss per share (SEK) -0.64 -0.80   -3.02  
Cash and cash equivalents  270.5 298.5   328.5  

 For further information, please contact:                    

  Tomas Leanderson, President and CEO
  Tel: +46 (0)46 19 20 95

 

  Hans Kolam, CFO
  Tel: +46 (0)46 19 20 44
  The report is also available at www.activebiotech.com		 Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00
   
Active Biotech AB Interim report January - March 2015


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire
HUG#1913651
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Actividentity Corp (MM) Charts.
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Actividentity Corp (MM) Charts.